Genetic clues for prostate cancer.
DNA signatures reveal genetic damage processes that drive aggressive prostate cancers and influence survival rates.
Anonymous
Key Points
1
Four of the eight mutational signatures were associated with tumors more likely to spread beyond the prostate, offering potential clues for identifying high-risk disease earlier.
2
The damage patterns were linked to failures in DNA-copying and DNA-repair machinery, as well as abnormalities in the prostate’s hormone-signaling system.
3
Geoff Macintyre said the central clinical challenge is not detecting prostate cancer but distinguishing men who may live with it for decades from those whose disease will become fatal.
4
Researchers emphasized the stakes of earlier risk classification: once prostate cancer has spread, the five-year survival rate falls to about 30%, according to co-author Jüri Reimand.
5
The study’s underlying analysis used whole-genome sequencing from the Pan Prostate Cancer Group cohort, comprising 1,001 donors and 1,172 tumor samples, with specialized analysis of structural variants, copy-number changes and chromothripsis.
An international team led by Spain's Centro Nacional de Investigaciones Oncológicas identified eight recurring DNA damage patterns that drive about 85% of prostate cancers Mirage News. By analyzing complete genomes from 959 tumors across seven countries, researchers found that the balance of these mutational signatures—not any single mutation—determines whether cancer stays slow-growing or becomes aggressive Mirage News. Four signatures were linked to tumors more likely to spread beyond the prostate, offering potential ways to catch high-risk disease earlier UK Head Topics.
The findings could transform how doctors assess prostate cancer risk. Currently, the central challenge is distinguishing men who may live with the disease for decades from those whose cancer turns fatal Mirage News. Once prostate cancer spreads, the five-year survival rate drops to about 30%, making early risk classification critical Mirage News. However, these genetic signatures are not yet ready for routine clinical use and require further validation before changing treatment decisions Archynetys.
Four Signatures Point to Aggressive Tumors
The research revealed that some mutational signatures predict whether cancer will spread aggressively. These patterns reflect failures in DNA-copying machinery, DNA-repair systems, and hormone-signaling abnormalities in the prostate Mirage News. Identifying these high-risk signatures early could let doctors separate patients needing aggressive treatment from those suited for watchful waiting UK Head Topics. The study analyzed not just point mutations but also DNA insertions, deletions, structural rearrangements, and broader genetic gains or losses Archynetys.
Most Cancers Driven by Multiple Damage Processes
A single genetic flaw rarely causes aggressive prostate cancer. Instead, most tumors result from several mutational processes working together Archynetys. The eight signatures identified by researchers represent distinct types of DNA damage, and their relative strength within each tumor helps predict behavior. Tumors dominated by certain signatures tend toward indolent growth, while those with different signature combinations become deadly Daily Mail.
Age and Ancestry Shape Genetic Patterns
The study found that some mutational signatures correlate with patient age and ancestry, including patterns more common in Black men Mirage News. This matters because a risk model built mainly from one population could misclassify patients in another, potentially worsening existing treatment disparities. Researchers stressed that diverse patient cohorts and ancestry-aware validation are essential before genomic signatures enter routine clinical practice Daily Mail.
Personalized Treatment Still Years Away
While the signatures offer biologically sound predictions, they are not yet validated for clinical use. Researchers emphasize that prospective studies are needed to prove the signatures actually improve patient outcomes and reduce unnecessary treatment Archynetys. The next step is testing whether using these genetic patterns to guide treatment decisions leads to better survival rates and lower rates of overtreatment UK Head Topics. The work opens a path toward precision medicine in prostate cancer but requires significant additional validation first.
Sentiment
Mostly NegativeNEGATIVENEUTRALPOSITIVE
Publishers
14
Articles
14
Reach
28
A
AnonymousAuthor
